Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV disease through their second RSV season. We s...

詳細記述

書誌詳細

出版年:	Pathogens
主要な著者:	Vaishali S. Mankad, Amanda Leach, Yue Chang, Ulrika Wählby Hamrén, Alexandre Kiazand, Robert J. Kubiak, Therese Takas, Tonya Villafana, Manish Shroff
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2024-06-01
主題:	infants monoclonal antibody nirsevimab respiratory syncytial virus safety
オンライン･アクセス:	https://www.mdpi.com/2076-0817/13/6/503